

Diarrhea References

- American Institute for Cancer Research. (2007). *Coping with the side effects of cancer treatment on your nutritional status*. Retrieved September 23, 2007, from http://www.aicr.org/site/PageServer?pagename=dc_cr_treatment#coping
- Benson, A.B., III, Ajani, J.A., Catalano, R.B., Engelking, C., Kornblau, S.M., Martenson, J.A., Jr., et al. (2004). Recommended guidelines for the treatment of cancer treatment-induced diarrhea. *Journal of Clinical Oncology*, 22(14), 2918–2926.
- Bowen, J.M., Stringer, A.M., Gibson, R.J., Yeoh, A.S., Hannam, S., & Keefe, D.M. (2007). VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. *Cancer Biology and Therapy*, 6(9), 1449–1454.
- Daniele, B., Perrone, F., Gallo, C., Pignata, S., De Martino, S., De Vivo, R., et al. (2001). Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: A double blind, placebo controlled, randomised trial. *Gut*, 48(1), 28–33.
- De Jong, F.A., Kehrer, D.F., Mathijssen, R.H., Creemers, G.J., de Bruijn, P., van Schaik, R.H., et al. (2006). Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: A double-blind, randomized, placebo-controlled study. *Oncologist*, 11(8), 944–954.
- Delia, P., Sansotta, G., Donato, V., Frosina, P., Messina, G., De Renzis, C., et al. (2007). Use of probiotics for prevention of radiation-induced diarrhea. *World Journal of Gastroenterology*, 13(6), 912–915.
- Dennert, G., & Horneber, M. (2006). Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. *Cochrane Database of Systematic Reviews* 2006, Issue 3. Art. No.: CD005037. DOI: 10.1002/14651858.CD005037.pub2.
- Eastern Cooperative Oncology Group. (2007, June). *ECOG common toxicity criteria*. Retrieved November 15, 2007, from <http://www.ecog.org/general/ctc.pdf>.
- Flieger, D., Klassert, C., Hainke, S., Keller, R., Kleinschmidt, R., & Fischback, W. (2007). Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. *Oncology*, 72(1–2), 10–16.
- Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., et al. (2005). Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. *Oncology*, 68(4–6), 326–332.
- Kehrer, D.F., Sparreboom, A., Verweij, J., de Bruijn, P., Nierop, C.A., van de Schraaf, J., et al. (2001). Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. *Clinical Cancer Research*, 7(5), 1136–1141.
- Kennedy, M., Bruninga, K., Mutlu, E.A., Losurdo, J., Choudhary, S., & Keshavarzian, A. (2001). Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C. *American Journal of Gastroenterology*, 96(4), 1080–1084.
- Kopp-Hoolihan, L. (2001). Prophylactic and therapeutic uses of probiotics: A review. *Journal of the American Dietetic Association*, 101(2), 229–238.
- Kornblau, S., Benson, A.B., III, Catalano, R., Champlin, R.E., Engelking, C., Field, M., et al. (2000). Management of cancer treatment-related diarrhea: Issues and therapeutic strategies. *Journal of Pain and Symptom Management*, 19(2), 118–129.
- Kozelsky, T.F., Meyers, G.E., Sloan, J.A., Shanahan, T.G., Dick, S.J., Moore, R.L., et al. (2003).

- Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. *Journal of Clinical Oncology*, 21(9), 1669–1674.
- Maeda, Y., Ohune, T., Nakamura, M., Yamasaki, M., Kiribayashi, Y., & Murakami, T. (2004). Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients. *Oncology Reports*, 12(3), 581–585.
- Maroun, J.A., Anthony, L.B., Blais, N., Burkes, R., Dowden, S.D., Dranitsaris, G., et al. (2007). Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. *Current Oncology*, 14(1), 13–20.
- Marteau, P.R., de Vrese, M., Cellier C.J., & Schrezenmeir, J. (2001). Protection from gastrointestinal diseases with the use of probiotics. *American Journal of Clinical Nutrition*, 72(Suppl. 2), 430S–436S.
- Martenson, J.A., Bollinger, J.W., Sloan, J.A., Novotny, P.J., Urias, R.E., Michalak, J.C., et al. (2000). Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial. *Journal of Clinical Oncology*, 18(6), 1239–1245.
- McCallum, P., & Polisena, C. (Eds.). (2000). *The clinical guide to oncology nutrition*. Chicago: American Dietetic Association.
- Michael, M., Brittain, M., Nagai, J., Feld, R., Hedley, D., Oza, A., et al. (2004). Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. *Journal of Clinical Oncology*, 22(21), 4410–4417.
- Moreno, V.V., Vidal, J.B., Alemany, H.M., Salvia, A.S., Serentill, M.L., Montero, I.C., et al. (2006). Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients. *Clinical and Translational Oncology*, 8(3), 208–212.
- Murphy, J., Stacey, D., Crook, J., Thompson, B., & Panetta, D. (2000). Testing control of radiation-induced diarrhea with a psyllium bulking agent: A pilot study. *Canadian Oncology Nursing Journal*, 10(3), 96–100.
- National Cancer Institute. (2006, August). *Common terminology criteria for adverse events (v.3.0)*. Retrieved November 13, 2007, from <http://ctep.cancer.gov/forms/CTCAEv3.pdf>.
- National Cancer Institute Cancer Therapy Evaluation Program. (2006). *Common terminology criteria for adverse events (version 3.0)*. Bethesda, MD: National Cancer Institute. Retrieved November 13, 2007, from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae3.pdf
- Osterlund, P., Ruotsalainen, T., Korpela, R., Saxelin, M., Ollus, A., Valta, P., et al. (2007). Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: A randomised study. *British Journal of Cancer*, 97(8), 1028–1034.
- Pilepich, M.V., Paulus, R., St. Clair, W., Barasacchio, R.A., Rostock, R., & Miller, R.C. (2006). Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapy. *American Journal of Clinical Oncology*, 29(2), 132–137.
- Rosenoff, S. (2004). Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. *Supportive Care in Cancer*, 12(8), 561–570.
- Rosenoff, S.H., Gabrail, N.Y., Conklin, R., Hohneker, J.A., Berg, W.J., Ghulam, W., et al.

- (2006). A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: Results of the STOP trial. *Journal of Supportive Oncology*, 4(6), 289–294.
- Savarese, D.M., Savy, G., Vahdat, L., Wischmeyer, P.E., & Corey, B. (2003). Prevention of chemotherapy and radiation toxicity with glutamine. *Cancer Treatment Reviews*, 29(6), 501–513.
- Savy, G.K. (2002). Glutamine supplementation: Heal the gut, help the patient. *Journal of Infusion Nursing*, 25(1), 65–69.
- Singh, B. (2007). Psyllium as therapeutic and drug delivery agent. *International Journal of Pharmaceutics*, 334(1–2), 1–14.
- Takeda, Y., Kobayashi, K., Akivama, Y., Soma, T., Handa, S., Kudoh, S., et al. (2001). Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. *International Journal of Cancer*, 92(2), 269–275.
- Topkan, E., & Karaoglu, A. (2006). Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. *Oncology*, 71(5–6), 354–360.
- Tsavaris, N., Kosmas, C., Vadiaka, M., Zonios, D., Papalambros, E., Papantoniou, N., et al. (2003). Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: A pilot study. *Journal of Pain and Symptom Management*, 26(3), 849–854.
- Urbancsek, H., Kazar, T., Mezes, I., & Neumann, K. (2001). Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. *European Journal of Gastroenterology and Hepatology*, 13(4), 391–396.
- World Health Organization. (n.d.). *WHO toxicity criteria by grade*. Retrieved November 15, 2007, from <http://www.fda.gov/cder/cancer/toxicityframe.htm>
- Yavuz, M.N., Yavuz, A.A., Aydin, F., Can, G., & Kavgaci, H. (2002). The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: A randomized controlled study. *International Journal of Radiation Oncology, Biology, Physics*, 54(1), 195–202.
- Zidan, J., Haim, N., Beny, A., Stein, M., Gez, E., & Kuten, A. (2001). Octreotide in the treatment of severe chemotherapy-induced diarrhea. *Annals of Oncology*, 12(2), 227–229.